Novartis Gets FDA Breakthrough Therapy Designation for Scemblix
By Pierre Bertrand
Novartis said the U.S. drug regulator decided to expedite the development of Scemblix, to treat adults newly diagnosed with leukemia.
The Swiss pharmaceutical company said the U.S. Food and Drug Administration designated the treatment as a breakthrough therapy for the third time.
Drugs that get designated as breakthrough therapies are those designed to treat serious conditions and that have shown "that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s)," according to the FDA's website.
This latest designation was based off of the Phase III ASC4FIRST study, in which the drug met both of its primary endpoints, the company said.
Novartis will present the full findings of the study at the end of May.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
May 10, 2024 09:42 ET (13:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase